中国经济网北京9月10日讯 舒泰神（300204.SZ）昨晚披露2025年度向特定对象发行股票预案称，本次发行募集 资金总额不超过（含）人民币125,300.00万元，在扣除相关发行费用后的募集资金净额将全部用于以下项目：创新 药物研发项目、补充流动资金。 | 序号 | 项目名称 | 总投资额 | 拟使用募集资金 | | --- | --- | --- | --- | | | 创新药物研发项目 | 91,300.00 | 88.300.00 | | 2 | 补充流动资金 | 37,000.00 | 37.000.00 | | | 合计 | 128,300.00 | 125,300.00 | 本次发行的发行对象不超过35名（含35名），包括符合规定条件的证券投资基金管理公司、证券公司、信托公 司、财务公司、保险机构投资者、合格境外机构投资者以及符合中国证监会规定的其他法人、自然人或其他合格的 投资者。其中，证券投资基金管理公司、证券公司、理财公司、保险公司、合格境外机构投资者、人民币合格境外 机构投资者以其管理的两只以上产品认购的，视为一个发行对象；信托公司作为发行对象的，只能以自有资金认 购。本次发行的所有发 ...

｜ 2025年9月10日星期三｜ NO.1国产九价HPV疫苗每支定价499元 NO.2太极集团获得司美格鲁肽临床试验批准 太极集团（600129）公告，全资子公司太极集团重庆涪陵制药厂有限公司收到国家药品监督管理局关于 司美格鲁肽注射液的《药物临床试验批准通知书》。本次涪陵制药厂获批临床的适应证为成人2型糖尿 病患者的血糖控制。 点评：太极集团子公司获批开展司美格鲁肽注射液临床试验，瞄准2型糖尿病治疗领域。此举意味着国 内糖尿病药物市场将迎来新竞争者，有望提升GLP-1类药物可及性。但目前该领域已成红海，太极集团 进度不占优势，后续竞争难度不容小觑。 NO.3百利天恒公布首个双抗ADC联用奥希替尼临床结果 9月9日上午，国产九价HPV疫苗在福建省厦门市海沧区开打，这标志着我国自主研发的九价HPV疫苗正 式投入使用，为9岁至45岁女性提供更加全面可及的宫颈癌防护选择。 该疫苗由厦门大学夏宁邵教授团队与万泰生物（603392）联合研发，采用全球首创的大肠埃希菌原核表 达系统。定价为每支499元，其中9岁至17岁人群接种两针，18岁至45岁女性需接种三针。在国产九价疫 苗上市前，国内接种九价HPV疫苗仅有一款美国进 ...

NO.1 国产九价HPV疫苗每支定价499元 9月9日上午，国产九价HPV疫苗在福建省厦门市海沧区开打，这标志着我国自主研发的九价HPV疫苗正 式投入使用，为9岁至45岁女性提供更加全面可及的宫颈癌防护选择。 2025年WCLC（世界肺癌大会）上，百利天恒公布iza-bren(BL-B01D1)联合奥希替尼治疗局晚期或转移 性EGFR突变非小细胞肺癌患者的II期研究。研究共纳入154例患者接受不同剂量iza-bren(EGFR×HER3双 抗ADC)联合奥希替尼治疗，其中40例患者接受iza-bren 2.5mg/kg D1D8 Q3W联合奥希替尼一线治疗。研 究结果显示，所有患者均为最佳应答：ORR（客观缓解率）100%，95%为cORR（确认的客观缓解率， 2例PR待确认），DCR（疾病控制率）100%，mDoR（中位缓解持续时间）未达到。 点评：这意味着，几乎接受治疗的40例患者肿瘤都显著缩小，在这40位患者中，有38位的缩小效果已经 被后续的复查确认是真实、持久的。100%的疾病控制率则意味着所有患者的病情都得到有效控制，中 位缓解持续时间没达到则表示肿瘤缩小效果仍然维持，还没有消失迹象。 该疫苗由厦 ...

Market Performance - The pharmaceutical and biotechnology index increased by 2.88% from September 1 to September 5, while the innovative drug index rose by 1.23% during the same period [3] - The Hang Seng Healthcare Index saw a significant increase of 7.07% in the same timeframe [3] Clinical Trials - A total of 48 clinical trial registration information was disclosed by the National Medical Products Administration from September 1 to September 5, with 21 trials in Phase II or above covering various fields such as oncology, dermatology, immunology, and digestion [4] New Drug Approvals - The first global innovative drug for delaying the progression of Type 1 diabetes was approved in China, developed by Sanofi [7] - The injection of Tzield (替利珠单抗) was approved for use in children aged 8 and above and adults with Stage 2 Type 1 diabetes to delay progression to Stage 3 [8] Rare Disease Treatments - The application for the injection of Vosoritide, developed by BioMarin Pharmaceutical for treating achondroplasia in children, has been accepted for review in China [10] - Achondroplasia is a rare skeletal development disorder with a global incidence of approximately 3.72 to 4.60 per 100,000, and it is included in China's rare disease directory [10] - Vosoritide is the first drug targeting the underlying cause of achondroplasia, with traditional treatments only alleviating symptoms [10] Company Insights - Shuyuan Pharmaceutical has seen a remarkable increase of over 700% in stock price over the past six months, driven by the development of a new drug for hemophilia [12][13] - The drug STSP-0601, currently in the approval stage, has shown a 12-hour effective hemostatic rate of 81.94% in Phase IIb trials for hemophilia patients with inhibitors, indicating its potential effectiveness [16][17] - The global market for hemophilia with inhibitors is estimated at approximately 27.7 billion yuan, with potential domestic sales exceeding 2 billion yuan [17] Industry Trends - The Chinese biopharmaceutical sector has rapidly advanced, with the country now being a leader in innovative drug development, accounting for 38% of global large pharmaceutical transactions in early 2025 [19][20] - The trend of Chinese innovative drugs entering global markets is expected to continue for another 12 to 18 months, emphasizing the importance of product quality and robust clinical data [20]

Market Performance - The pharmaceutical and biotechnology index increased by 2.88% from September 1 to September 5, while the innovative drug index rose by 1.23% during the same period [1] - The Hang Seng Healthcare Index saw a significant increase of 7.07% [1] IPO Activity - There were no new IPO announcements for A-shares or Hong Kong stocks during the week [2] Clinical Trials - A total of 48 clinical trial registration information was disclosed by the National Medical Products Administration (NMPA) from September 1 to September 5, with 21 trials in Phase II or above covering various fields such as oncology, dermatology, immunology, and digestion [2] New Drug Approvals - The first global drug to delay the progression of Type 1 diabetes, Tzield (替利珠单抗注射液), was approved in China for patients aged 8 and above with Type 1 diabetes stage 2 [3] - BioMarin Pharmaceutical's injection drug Vusolimab for treating achondroplasia in children has had its application accepted by the NMPA, addressing a rare skeletal development disorder with a global incidence rate of 3.72 to 4.60 per 100,000 [4] Market Trends - Shuyatong, a leading innovative drug company, experienced a 700% increase in stock price over six months, but recently saw a decline of 23.98% in one week [7] - The drug STSP-0601 for hemophilia, currently in the approval stage, demonstrated a 12-hour effective hemostatic rate of 81.94% in clinical trials, indicating its potential in the market for hemophilia treatments [7][8] Industry Insights - Chen Zhisheng, CEO of WuXi Biologics, highlighted the rapid growth of China's innovative drug sector, with a projected transaction amount of $21.6 billion in the first five months of 2025, accounting for 38% of global large pharmaceutical transactions [9] - The trend of Chinese innovative drugs entering global markets is expected to continue for another 12 to 18 months, emphasizing the importance of product quality and robust clinical data [10]

证券日报网讯 9月9日晚间，舒泰神发布公告称，公司第六届监事会第九次会议审议通过了《关于公司 符合向特定对象发行股票条件的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 9月9日晚间，舒泰神发布公告称，公司第六届董事会第九次会议审议通过了《关于公司 2025年度向特定对象发行股票预案的议案》等多项议案。 （文章来源：证券日报） ...

Fundraising and Investment - Shuyatian plans to raise no more than 1.253 billion yuan through a private placement for innovative drug research and development projects and to supplement working capital [1] - Sanbo Brain Science intends to invest 57 million yuan in a fund focused on brain science, which aims to raise a total of 300 million yuan [5] Clinical Trials and Product Development - Taiji Group's subsidiary received approval for clinical trials of Semaglutide injection for type 2 diabetes, with a cumulative R&D investment of approximately 44.1834 million yuan [2] Production and Operations - Zhongjin Gold announced that its subsidiary in Inner Mongolia has resumed production, stating that the previous suspension did not significantly impact overall operations and performance [3] Shareholding Changes - Xibu Gold reported that its shareholder, Tulu Fan Jinyuan Mining Co., reduced its stake by 1% from September 8 to September 9, completing the reduction plan [4] - Various companies reported changes in shareholding, including Shen Keda and Yongxin Optical, with plans for both increases and decreases in shareholdings [7] Major Contracts and Projects - Apac Co. received a total contract amount of 514 million yuan for brake and EPB projects [8] - Jiangnan Water and Ruina Intelligent also reported significant contract wins, with amounts of 368 million yuan and 225 million yuan respectively [8]

每经AI快讯，舒泰神（SZ 300204，收盘价：38.41元）9月9日晚间发布公告称，本次向特定对象发行股 票相关事项已经公司2025年9月8日召开的第六届董事会第九次会议审议通过，本次发行的发行对象不超 过35名（含35名），其中，本次发行的股票数量将按照募集资金总额除以发行价格确定，且不超过公司 本次发行前总股本的30%（含本数），即公司发行股份数上限约为1.43亿股（含本数），并以中国证监 会关于本次发行的注册批复文件为准。本次发行的发行价格不低于定价基准日前20个交易日公司股票交 易均价的80%。创新药物研发项目，总投资9.13亿元，拟投入募集资金8.83亿元；补充流动资金项目， 总投资3.7亿元，拟投入募集资金3.7亿元。 2024年1至12月份，舒泰神的营业收入构成为：产品销售占比100.0%。 每经头条（nbdtoutiao）——雷军挥泪"斩"王腾，小米爱将泄密"失街亭"，大厂正风肃纪"拼牙口" （记者 王晓波） 截至发稿，舒泰神市值为184亿元。 ...

智通财经APP讯，舒泰神(300204.SZ)发布2025 年度向特定对象发行股票预案，本次发行募集资金总额 不超过(含)人民币12.53亿元，在扣除相关发行费用后的募集资金净额将全部用于以下项目：8.83亿元用 于创新药物研发项目；3.7亿元用于补充流动资金。 ...